226 related articles for article (PubMed ID: 31344647)
1. Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Oct; 175():112742. PubMed ID: 31344647
[TBL] [Abstract][Full Text] [Related]
2. Part 2: Physicochemical characterization of bevacizumab in 2 mg/mL antibody solutions as used in human i.v. administration: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Nov; 176():112802. PubMed ID: 31446298
[TBL] [Abstract][Full Text] [Related]
3. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
4. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A
Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605
[TBL] [Abstract][Full Text] [Related]
5. Stability of infliximab solutions in different temperature and dilution conditions.
Tokhadze N; Chennell P; Le Basle Y; Sautou V
J Pharm Biomed Anal; 2018 Feb; 150():386-395. PubMed ID: 29287266
[TBL] [Abstract][Full Text] [Related]
6. Characterization of bevacizumab by dynamic light scattering while maintaining its native structure.
Akbas S; Sahin A; Calis S; Oncel H; Capan Y
Pharmazie; 2018 Jul; 73(7):369-374. PubMed ID: 30001769
[TBL] [Abstract][Full Text] [Related]
7. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes.
Zhang L; Yu L; Xu Y; Qin P; Shen P; Liu K; Fei M; Wang H; Cao Y; Lu L; Gao W; Zhang Z
Anal Bioanal Chem; 2023 Jul; 415(17):3341-3362. PubMed ID: 37162525
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
[TBL] [Abstract][Full Text] [Related]
9. Novel Mechanism of Glass Delamination in Type 1A Borosilicate Vials Containing Frozen Protein Formulations.
Jiang G; Goss M; Li G; Jing W; Shen H; Fujimori K; Le L; Wong L; Wen ZQ; Nashed-Samuel Y; Riker K; Germansderfer A; Tsang P; Ricci M
PDA J Pharm Sci Technol; 2013; 67(4):323-35. PubMed ID: 23872443
[TBL] [Abstract][Full Text] [Related]
10. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
Seo N; Polozova A; Zhang M; Yates Z; Cao S; Li H; Kuhns S; Maher G; McBride HJ; Liu J
MAbs; 2018; 10(4):678-691. PubMed ID: 29553864
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
Park D; Kim J; Yun J; Park SJ
Adv Ther; 2020 Oct; 37(10):4308-4324. PubMed ID: 32816233
[TBL] [Abstract][Full Text] [Related]
12. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin (bevacizumab), Remicade (infliximab) and Herceptin (trastuzumab).
Peters BJ; Capelle MA; Arvinte T; van de Garde EM
MAbs; 2013; 5(1):162-70. PubMed ID: 23255057
[TBL] [Abstract][Full Text] [Related]
13. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
[TBL] [Abstract][Full Text] [Related]
14. Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass-spectrometry-based approach.
Brown KA; Rajendran S; Dowd J; Wilson DJ
Drug Test Anal; 2019 Aug; 11(8):1207-1217. PubMed ID: 31041833
[TBL] [Abstract][Full Text] [Related]
15. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev
Weiser S; Burns C; Zartler ER
J Oncol Pharm Pract; 2023 Jul; 29(5):1032-1043. PubMed ID: 35312402
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of aggregates analysis method in analytical similarity assessment of HLX04 vs Avastin®.
Fei M; Zhang Q; Zhang L; Zhu X; Du C; Zhang Z
J Pharm Biomed Anal; 2023 Jan; 223():115121. PubMed ID: 36308924
[TBL] [Abstract][Full Text] [Related]
17. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2021 Sep; 73():41-56. PubMed ID: 34593306
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.
Xu Y; Xie L; Zhang E; Gao W; Wang L; Cao Y; Xie MH; Jiang W; Liu S
MAbs; 2019 Apr; 11(3):606-620. PubMed ID: 30794092
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
Joshi S; Rathore AS
BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]